Research Options:
Week of Expected Pricing Pending
Company Name PHARMING GROUP NV
Proposed Ticker PHAR
CUSIP N/A
Business Description A commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The flagship of our portfolio is our recombinant human C1 esterase inhibitor, or rhC1INH, franchise. C1INH is a naturally occurring protein that downregulates the complement cascade in order to control swelling in affected tissues. Our lead product, RUCONEST® is the first and only plasma-free rhC1INH protein replacement therapy.
Lead Underwriter N/A
Co-Managers N/A
Initial Shares 899,802
Revised Initial Shares N/A
Initial Price $12.10-$12.10
Revised Price N/A
Final Price N/A
Final Ticker N/A

 

 
   
  © 2024 ICE Data Services. All rights reserved.